[Immunotherapy in non-allergic diseases].
Therapy of immunological diseases such as Primary immunodeficiencies (PID) and Autoimmune diseases has improved greatly in the last years due to a better knowledge of the mechanisms involved in each one which guide new therapeutic interventions. Substitution therapy with iv. Gammaglobulin, transplantation of haematopoietic progenitor cells and the use of some citokines to improve immune response has changed prognosis and quality of life of many PID. Immune modulation with anti-proliferative drugs and the use of anti-citokines or cytokine-receptor MoAb have been introduced in autoimmune diseases with very good response. Many other molecules will be introduced in therapy of these diseases in a near future.
Español
T
T
Unidad de Alergología, Hospital Valle Hebrón, Barcelona, España.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D010949:Plasma; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors / Q000276:immunology
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D018121:Receptors, Cytokine
Inmunoterapia en patología no alérgica.